1. NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY. Issue 2 (22nd June 2018) Authors: Shih, Chie-Schin; Blakely, Jaishri; Clapp, Wade; Wolters, Pam; Dombi, Eva; Cutter, Gary; Ullrich, Nichole; Allen, Jeffrey; Packer, Roger; Goldman, Stewart; Gutmann, David; Plotkin, Scott; Rosser, Tena; Robertson, Kent; Widemann, Brigitte; Korf, Bruce; Fisher, Michael Journal: Neuro-oncology Issue: Volume 20:Issue 2(2018)supplement 2 Page Start: i142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. (16th August 2016) Authors: Hanemann, C. Oliver; Blakeley, Jaishri O.; Nunes, Fabio P.; Robertson, Kent; Stemmer-Rachamimov, Anat; Mautner, Victor; Kurtz, Andreas; Ferguson, Michael; Widemann, Brigitte C.; Evans, D. Gareth; Ferner, Rosalie; Carroll, Steven L.; Korf, Bruce; Wolkenstein, Pierre; Knight, Pamela; Plotkin, Scott R. Journal: Neurology Issue: Volume 87:Number 7(2016)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗